Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy

Next Previous
X
Search
Trial Profile

A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atacicept (Primary)
  • Indications IgA nephropathy; Proteinuria
  • Focus Adverse reactions
  • Acronyms JANUS
  • Sponsors EMD Serono Research & Development Institute; Merck Serono

    • Most Recent Events

    • 17 Oct 2022 According to a Vera Therapeutics media release, data from this trial will be presented at the American Society of Nephrology Kidney Week 2022 Annual Meeting.
    • 20 May 2022 According to a Vera Therapeutics media release, data from this trial presented at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress, 2022.
    • 20 May 2022 Results published in the Vera Therapeutics Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top